Zevra Therapeutics, Inc. (ZVRA) Stock

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is led by CEO Neil F. McFarlane, employs 59 people, headquartered in US, publicly traded since 2015.

Zevra Therapeutics, Inc. (ZVRA) stock trades at $9.81 with a market capitalization of $582.55M. The stock is valued at a price-to-earnings (P/E) ratio of 10.40, price-to-book of 2.72, price-to-sales of 4.34. Over the past 52 weeks the stock has ranged between $8.01 and $15.04, and currently trades 34.8% below its 52-week high.

On profitability, Zevra Therapeutics, Inc. generates a return on equity (ROE) of 32.77%, above the typical market range of roughly 12-15%, return on capital employed of 15.38%, an operating margin of -3.77%, a net profit margin of 42.82%.

Zevra Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Zevra Therapeutics, Inc. reported revenue of $0 rising to $106.0M. Compounded, revenue has grown 52.1% a year over five years, 119.7% over three, 341.7% over the last twelve months. Net profit rose to $83.0M.

The most recent net margin is 42.82%. On a trailing twelve-month basis to Jun '26, revenue is $136.0M and net profit $58.0M.

Borrowings fell from $92.0M to $63.0M, cash from operations was $-2.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -65.8% over five years, and was 53.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Zevra Therapeutics, Inc. (ZVRA) — frequently asked questions